Research shows mRNA vaccines saved millions of lives during the COVID-19 pandemic. Now scientists are using that Nobel ...

Pfizer delivered a strong Q2 earnings beat, raising FY2025 guidance and demonstrating effective cost-cutting. Learn why PFE ...

At first glance, Pfizer delivered a strong Q2 and upped its 2025 full-year EPS guidance. Click here to find out why I rate ...

The tariff threat come just a few days after the White House sent letters to major drugmakers demanding slashed prices for US ...

Q2 2025 Earnings Call Transcript August 6, 2025 Arvinas, Inc. beats earnings expectations. Reported EPS is $-0.83836, ...

86% align with Pfizer's commitment to social responsibility 83% rate HR practices as people-focused 94% alignment with best ...

The Nobel Prize winning scientist behind mRNA vaccine technology has attacked the US health secretary’s plan to effectively ...

Health Secretary Robert F. Kennedy Jr.’s decision this week to cancel hundreds of millions of dollars in mRNA vaccine funding ...

Pfizer (NYSE:PFE) develops and sells biopharmaceutical products, including vaccines, treatments for infectious diseases, ...

PFIZER said its full-year profit should benefit from cost cuts across its research and manufacturing operations after posting higher-than-expected second-quarter earnings on Tuesday.

Drugmaker Viatris beat Wall Street estimates for second-quarter profit and revenue on Thursday, helped by demand for its products in China, sending its shares up nearly 5% in early trading.